Publications by authors named "V Boni"

Claim this Profile
D
Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity.
Jacqueline H Starrett, Eric L Allen, Melissa Neal, Samhita Iyer, Qing Ye, Valentina Boni

Mol Cancer Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial.
Scott Kopetz, Valentina Boni, Ken Kato, Kanwal P S Raghav, Maria Vieito

Nat Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabogratinib (TYRA-300), an FGFR3 isoform-selective inhibitor: preclinical and initial clinical evidence of anti-tumor activity.
Jacqueline H Starrett, Eric L Allen, Melissa Neal, Samhita Iyer, Qing Ye, Valentina Boni

Mol Cancer Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.
Bob T Li, Leena Gandhi, Vignesh Ravichandran, Benjamin Besse, Julien Mazières, Valentina Boni

Clin Lung Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial.
Emiliano Calvo, Valentina Boni, Olivier Dumas, Sang Joon Shin, Seth D Rosen

J Immunother Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis